Healthcare law company Frier Levitt has analyzed FDA enforcement steps in opposition to “exploration only” peptide distributors. Their summary: the FDA considers an item’s classification according to its intended use, not its disclaimers. When Sites incorporate dosage guides, reconstitution Guidance